JP2008508279A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008508279A5 JP2008508279A5 JP2007523596A JP2007523596A JP2008508279A5 JP 2008508279 A5 JP2008508279 A5 JP 2008508279A5 JP 2007523596 A JP2007523596 A JP 2007523596A JP 2007523596 A JP2007523596 A JP 2007523596A JP 2008508279 A5 JP2008508279 A5 JP 2008508279A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- dosage form
- vitamin
- release pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 238000013268 sustained release Methods 0.000 claims 9
- 239000012730 sustained-release form Substances 0.000 claims 9
- 239000002552 dosage form Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 238000002347 injection Methods 0.000 claims 5
- 239000007924 injection Substances 0.000 claims 5
- 239000006203 subcutaneous dosage form Substances 0.000 claims 5
- 229930003316 Vitamin D Natural products 0.000 claims 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 4
- 235000019166 vitamin D Nutrition 0.000 claims 4
- 239000011710 vitamin D Substances 0.000 claims 4
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 4
- 229940046008 vitamin d Drugs 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 239000012190 activator Substances 0.000 claims 3
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 208000017169 kidney disease Diseases 0.000 claims 3
- 239000006186 oral dosage form Substances 0.000 claims 3
- 102000009310 vitamin D receptors Human genes 0.000 claims 3
- 108050000156 vitamin D receptors Proteins 0.000 claims 3
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 2
- 102000015427 Angiotensins Human genes 0.000 claims 2
- 108010064733 Angiotensins Proteins 0.000 claims 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 2
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims 2
- 229960002478 aldosterone Drugs 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 235000020964 calcitriol Nutrition 0.000 claims 2
- 239000011612 calcitriol Substances 0.000 claims 2
- 229960005084 calcitriol Drugs 0.000 claims 2
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims 2
- 229960002061 ergocalciferol Drugs 0.000 claims 2
- 229960000987 paricalcitol Drugs 0.000 claims 2
- BPKAHTKRCLCHEA-UBFJEZKGSA-N paricalcitol Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-UBFJEZKGSA-N 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 235000001892 vitamin D2 Nutrition 0.000 claims 2
- 239000011653 vitamin D2 Substances 0.000 claims 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/901,660 US20050148557A1 (en) | 2003-07-29 | 2004-07-28 | Use of Vitamin Ds to treat kidney disease |
| US10/974,243 US20050124591A1 (en) | 2003-07-29 | 2004-10-27 | Use of vitamin Ds to treat kidney disease |
| PCT/US2005/024446 WO2006019659A1 (en) | 2004-07-28 | 2005-07-08 | Use of vitamin ds to treat kidney disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008508279A JP2008508279A (ja) | 2008-03-21 |
| JP2008508279A5 true JP2008508279A5 (OSRAM) | 2008-10-02 |
Family
ID=34982541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007523596A Withdrawn JP2008508279A (ja) | 2004-07-28 | 2005-07-08 | 腎疾患を治療するためのビタミンｄの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20050124591A1 (OSRAM) |
| EP (1) | EP1786407A1 (OSRAM) |
| JP (1) | JP2008508279A (OSRAM) |
| CA (1) | CA2575155A1 (OSRAM) |
| WO (1) | WO2006019659A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007001969A1 (en) * | 2005-06-27 | 2007-01-04 | The General Hospital Corporation | Vitamin d deficiency and dialysis |
| EP1945185B1 (en) * | 2005-10-12 | 2016-02-03 | Proventiv Therapeutics, LLC | Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency |
| SI1993559T1 (sl) | 2006-02-03 | 2017-01-31 | Opko Renal, Llc | Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3 |
| DK3357496T3 (da) | 2006-06-21 | 2020-05-11 | Opko Ireland Global Holdings Ltd | Terapi ved brug af vitamin d-repletteringsmiddel og vitamin d-hormonsubstitutionsmiddel |
| WO2008103420A1 (en) * | 2007-02-21 | 2008-08-28 | The Regents Of The University Of Michigan | Compositions and methods for tranquilizing heart muscle |
| ES3047207T3 (en) | 2007-04-25 | 2025-12-03 | Opko Renal Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
| PT2148684E (pt) * | 2007-04-25 | 2013-04-19 | Cytochroma Inc | Método de tratamento para a insuficiência e deficiência de vitamina d |
| CA2684778C (en) * | 2007-04-25 | 2017-09-05 | Cytochroma Inc. | Methods and compounds for vitamin d therapy |
| PT2148661E (pt) | 2007-04-25 | 2013-03-06 | Proventiv Therapeutics Llc | Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso |
| AU2008323903B2 (en) * | 2007-11-06 | 2013-12-05 | The Salk Institute For Biological Studies | Use of vitamin D receptor agonists and precursors to treat fibrosis |
| US8318708B2 (en) * | 2007-11-06 | 2012-11-27 | Salk Institute For Biological Studies | Use of vitamin D receptor agonists, ligands, and precursors to treat pancreatic fibrosis |
| CN106853250A (zh) | 2008-04-02 | 2017-06-16 | 赛特克罗公司 | 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒 |
| CA2764577C (en) | 2009-08-03 | 2017-12-19 | Wisconsin Alumni Research Foundation | Method of preventing renal disease and treating symptoms thereof |
| US11672809B2 (en) | 2010-03-29 | 2023-06-13 | Eirgen Pharma Ltd. | Methods and compositions for reducing parathyroid levels |
| EP2702155B9 (en) | 2011-04-25 | 2020-01-01 | Regulus Therapeutics Inc. | Microrna compounds and methods for modulating mir-21 activity |
| PH12023550488A1 (en) | 2012-04-25 | 2024-06-24 | Sanofi Sa | Microrna compounds and methods for modulating mir-21 activity |
| HK1206600A1 (en) | 2012-06-29 | 2016-01-15 | Wisconsin Alumni Research Foundation | USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM |
| UA116639C2 (uk) * | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| EP2988752A4 (en) | 2013-04-24 | 2017-01-18 | Salk Institute for Biological Studies | Vitamin d receptor/smad genomic circuit gates fibrotic response |
| CN105451818A (zh) | 2013-06-05 | 2016-03-30 | 萨克生物研究学院 | 治疗涉及cxcl12活性的疾病的维生素d受体激动剂 |
| EP2818176A1 (en) | 2013-06-27 | 2014-12-31 | Virbac | Composition for the treatment of progressive renal diseases |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| US9539264B2 (en) | 2014-12-30 | 2017-01-10 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics |
| US10369161B2 (en) | 2014-12-30 | 2019-08-06 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism |
| WO2017182237A1 (en) | 2016-03-28 | 2017-10-26 | Opko Ireland Global Holdings, Limited | Methods of vitamin d treatment |
| WO2019023149A1 (en) | 2017-07-24 | 2019-01-31 | Salk Institute For Biological Studies | USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES |
| EP3748362B1 (en) * | 2019-06-06 | 2023-10-11 | Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz | In vitro method for detecting renal disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6747008B1 (en) * | 2000-06-19 | 2004-06-08 | University Of Southern California | Methods for treating and preventing alopecia |
| FR2825087B1 (fr) * | 2001-05-22 | 2005-01-14 | Galderma Res & Dev | Analogues de la vitamine d |
-
2004
- 2004-10-27 US US10/974,243 patent/US20050124591A1/en not_active Abandoned
-
2005
- 2005-07-08 EP EP05769600A patent/EP1786407A1/en not_active Withdrawn
- 2005-07-08 WO PCT/US2005/024446 patent/WO2006019659A1/en not_active Ceased
- 2005-07-08 JP JP2007523596A patent/JP2008508279A/ja not_active Withdrawn
- 2005-07-08 CA CA002575155A patent/CA2575155A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008508279A5 (OSRAM) | ||
| WO2008027557A3 (en) | Topiramate compositions and methods of enhancing its bioavailability | |
| EA200900264A1 (ru) | Композиции флибансерина и способ их приготовления | |
| JP2009539841A5 (OSRAM) | ||
| NO20074509L (no) | Kombinasjon av organiske forbindelser | |
| EA200800161A1 (ru) | Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций | |
| EA200701575A1 (ru) | Формуляция леветирацетама длительного высвобождения | |
| WO2005070462A3 (en) | Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use | |
| DE60032749D1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
| WO2008050329A3 (en) | Novel sirnas and methods of use thereof | |
| WO2008022256A3 (en) | Methods and compositions for preventing or treating age-related diseases | |
| JP2008538564A5 (OSRAM) | ||
| AR075148A1 (es) | Formulacion de rasagilina de liberacion retardada. proceso para fabricar citrato de rasagilina | |
| IL194885A0 (en) | Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an nsaid | |
| WO2007145941A8 (en) | Administration of anti-cd3 antibodies in the treatment of autoimmune diseases | |
| WO2006037031A3 (en) | Formulations and methods for treatment of inflammatory diseases | |
| BRPI0922789A2 (pt) | peptídeo de ligação de albumina intermediador para reconhecimento de doença | |
| JP2006513184A5 (OSRAM) | ||
| NZ592615A (en) | Method for treating or preventing thrombosis using 150 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy | |
| WO2007111945A3 (en) | Method for management of diarrhea | |
| NZ597317A (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application | |
| JP2009517411A5 (OSRAM) | ||
| EP1781277A4 (en) | COMBINATION PREPARATION | |
| RU2009139186A (ru) | Применение гиалуронидазы для профилактики или лечения артериальной гипертензии или сердечной недостаточности | |
| AR054238A1 (es) | Composicion farmaceutica que contiene una biguanida y un derivado de tiazolidindiona |